​

Incyte (INCY) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

INCY Stock Forecast

Incyte (INCY) stock forecast, based on 44 Wall Street analysts, predicts a 12-month average price target of $134.40, with a high of $157.00 and a low of $104.00. This represents a 14.94% increase from the last price of $116.93.

$90 $104 $118 $132 $146 $160 High: $157 Avg: $134.4 Low: $104 Last Closed Price: $116.93

INCY Stock Rating

Incyte stock's rating consensus is Buy, based on 44 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 23 Buy (52.27%), 20 Hold (45.45%), 1 Sell (2.27%), and 0 Strong Sell (0.00%).

Buy
Total 44 1 20 23 Strong Sell Sell Hold Buy Strong Buy

INCY Price Target Upside V Benchmarks

TypeNameUpside
StockIncyte14.94%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts61849
Avg Price Target$136.17$134.44$117.96
Last Closing Price$116.93$116.93$116.93
Upside/Downside16.45%14.97%0.88%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 26210151-28
Sep, 26210151-28
Aug, 2629151-27
Jul, 2629141-26
Jun, 2629151128
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 16, 2026Raymond James$152.00$113.2734.19%29.99%
Oct 14, 2026Srikripa DevarakondaTruist Financial$115.00$111.443.19%-1.65%
Oct 08, 2026RBC Capital$114.00$111.791.98%-2.51%
Oct 05, 2026Ashwani VermaUBS$127.00$113.0312.36%8.61%
Oct 05, 2026Stephen WilleyStifel Nicolaus$157.00$115.3036.17%34.27%
Sep 28, 2026Mitchell KapoorH.C. Wainwright$152.00$123.8922.69%29.99%
Aug 20, 2026Canaccord Genuity$152.00$128.4718.32%29.99%
Aug 17, 2026Allison BratzelPiper Sandler$130.00$120.168.19%11.18%
Aug 13, 2026Bernstein$104.00$120.77-13.89%-11.06%
Aug 03, 2026Andrew BerensLeerink Partners$155.00$119.5229.69%32.56%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Oct 21, 2026Cowen & Co.BuyBuyhold
Oct 13, 2026BenchmarkBuyBuyhold
Oct 08, 2026RBC CapitalSector PerformSector Performhold
Oct 05, 2026UBSNeutralNeutralhold
Sep 28, 2026UBSBuyBuyhold
Sep 11, 2026Cantor FitzgeraldNeutralNeutralhold
Sep 01, 2026BMO CapitalMarket PerformMarket Performhold
Aug 20, 2026BenchmarkBuyBuyhold
Aug 17, 2026Piper SandlerOverweightOverweighthold
Aug 13, 2026BernsteinMarket PerformMarket Performhold

Financial Forecast

EPS Forecast

$0 $3 $6 $9 $12 $15 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$4.30$1.53$2.67$0.16$6.59---
Avg Forecast$2.58$1.76$3.60$1.26$5.90$7.18$8.78$10.69
High Forecast$2.76$1.86$3.70$1.53$6.91$9.31$11.60$11.43
Low Forecast$2.47$1.65$3.50$1.01$4.97$5.47$6.71$10.10
Surprise %66.67%-13.07%-25.83%-87.30%11.69%---

Revenue Forecast

$3B $3B $4B $5B $6B $7B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$2.99B$3.39B$3.70B$4.24B$5.14B---
Avg Forecast$2.92B$3.34B$3.69B$4.20B$4.64B$5.05B$5.46B$5.94B
High Forecast$3.08B$3.49B$3.73B$4.25B$4.89B$5.10B$5.52B$6.26B
Low Forecast$2.83B$3.18B$3.66B$4.13B$4.45B$5.01B$5.40B$5.70B
Surprise %2.12%1.69%0.18%0.87%10.90%---

Net Income Forecast

$0 $600M $1B $2B $2B $3B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$948.58M$340.66M$597.60M$32.62M$1.29B---
Avg Forecast$1.33B$1.45B$597.60M$287.16M$1.34B$1.26B$1.52B$2.41B
High Forecast$1.60B$1.74B$717.12M$345.89M$1.56B$2.10B$2.62B$2.58B
Low Forecast$1.07B$1.16B$478.08M$228.42M$1.12B$1.24B$1.52B$2.28B
Surprise %-28.88%-76.49%--88.64%-4.12%---

INCY Forecast FAQ

Is Incyte stock a buy?

Incyte stock has a consensus rating of Buy, based on 44 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 23 Buy, 20 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that Incyte is a favorable investment for most analysts.

What is Incyte's price target?

Incyte's price target, set by 44 Wall Street analysts, averages $134.4 over the next 12 months. The price target range spans from $104 at the low end to $157 at the high end, suggesting a potential 14.94% change from the previous closing price of $116.93.

How does Incyte stock forecast compare to its benchmarks?

Incyte's stock forecast shows a 14.94% upside, underperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Incyte over the past three months?

  • October 2026: 7.14% Strong Buy, 35.71% Buy, 53.57% Hold, 3.57% Sell, 0% Strong Sell.
  • September 2026: 7.14% Strong Buy, 35.71% Buy, 53.57% Hold, 3.57% Sell, 0% Strong Sell.
  • August 2026: 7.41% Strong Buy, 33.33% Buy, 55.56% Hold, 3.70% Sell, 0% Strong Sell.

What is Incyte’s EPS forecast?

Incyte's average annual EPS forecast for its fiscal year ending in December 2026 is $7.18, marking a 8.95% increase from the reported $6.59 in 2025. Estimates for the following years are $8.78 in 2027, and $10.69 in 2028.

What is Incyte’s revenue forecast?

Incyte's average annual revenue forecast for its fiscal year ending in December 2026 is $5.05B, reflecting a -1.69% decrease from the reported $5.14B in 2025. The forecast for 2027 is $5.46B, and $5.94B for 2028.

What is Incyte’s net income forecast?

Incyte's net income forecast for the fiscal year ending in December 2026 stands at $1.26B, representing a -2.14% decrease from the reported $1.29B in 2025. Projections indicate $1.52B in 2027, and $2.41B in 2028.